Examkin

Soru

Zorluk: OrtaGeneral Internal Medicine

A 65-year-old woman is brought to the emergency department due to progressive confusion, generalized weakness, and recurrent vomiting over the past 4 days. Her medical history is significant for breast cancer treated with a lumpectomy, radiation, and chemotherapy 6 years ago. Vital signs show a temperature of 37.1°C (98.8°F), blood pressure of 100/60 mm Hg, heart rate of 112/min, and respiratory rate of 14/min. Physical examination is notable for dry mucous membranes, delayed capillary refill, and lethargy.

Laboratory evaluation reveals the following:

Laboratory TestResultReference Range
Serum calcium15.6 mg/dL8.4-10.2 mg/dL
Serum albumin3.8 g/dL3.5-5.0 g/dL
Serum creatinine2.1 mg/dL0.6-1.1 mg/dL

An electrocardiogram demonstrates a shortened QT interval.

Arrange the following management steps in the most appropriate temporal sequence for the acute stabilization and definitive therapy of this patient, from initial action to long-term management.

  1. 1Initiate aggressive intravenous volume expansion with 0.9% normal saline
  2. 2Administer calcitonin
  3. 3Administer an intravenous bisphosphonate (e.g., zoledronic acid)
  4. 4Direct systemic therapy against the underlying relapsed malignancy

Cevap

The correct sequential order is: 1) Initiate aggressive intravenous volume expansion with 0.9% normal saline, 2) Administer calcitonin, 3) Administer an intravenous bisphosphonate, 4) Direct systemic therapy against the underlying relapsed malignancy.
The proper sequence for managing severe symptomatic hypercalcemia (> 14 mg/dL) begins with aggressive intravenous hydration (isotonic saline) to reverse severe volume depletion and improve renal calcium excretion. Because hydration alone is insufficient, calcitonin is administered to rapidly lower calcium levels within hours. Intravenous bisphosphonates (like zoledronic acid) are given to provide a sustained reduction in serum calcium, but because they take 48-72 hours to achieve full effect and can be nephrotoxic in dehydrated patients, they are administered following initial volume expansion. Finally, treating the underlying malignancy provides definitive, long-term resolution of the condition.

Adım Adım Çözüm

1
Assess the clinical presentation and laboratory data.
The patient has severe symptomatic hypercalcemia (calcium > 14 mg/dL) complicated by profound dehydration and acute kidney injury.
Identifying the severity of hypercalcemia and its physiological impact on volume status dictates the urgency and sequence of interventions.
2
Select the most critical initial stabilization measure.
Intravenous volume expansion with isotonic saline is chosen as the first step.
Hypercalcemia causes a nephrogenic diabetes insipidus-like state, leading to severe volume depletion. Restoring intravascular volume improves glomerular filtration and increases renal calcium clearance.
3
Select the rapid-acting pharmacological therapy.
Calcitonin is administered next.
Calcitonin acts rapidly (within hours) to inhibit osteoclast function, bridging the temporal gap before long-acting agents take full effect.
4
Select the long-acting pharmacological therapy.
An intravenous bisphosphonate is administered.
Bisphosphonates provide sustained calcium reduction but take 48-72 hours to reach maximum effect. They must follow initial hydration to reduce the risk of nephrotoxicity.
5
Determine the definitive long-term management.
Systemic therapy for the underlying malignancy is planned.
Treating the root cause (relapsed breast cancer) is essential to prevent recurrent hypercalcemia once the acute crisis is managed.

Anahtar Kavram

The acute management of severe symptomatic hypercalcemia requires sequential, targeted interventions: initial aggressive volume expansion, followed by rapid-acting agents (calcitonin), long-acting agents (bisphosphonates), and ultimately treating the underlying malignant cause.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

General Internal Medicine

Bu konudan daha fazla soru